
- Home
- WISTEM2d
What WiSTEM²D is—and why it matters
Johnson & Johnson has invested in the STEM2D workforce to giving them the tools, resources and opportunities to succeed at work and at home since our founding more than 138 years ago.
Furthering that commitment, in 2015 we launched our WiSTEM2D initiative. WiSTEM2D stands for Winning in Science, Technology, Engineering, Math, Manufacturing and Design. We believe the STEM2D workforce can be catalysts for creating healthier people, healthier communities and a healthier world.
At J&J, we are dedicated to the values in Our Credo. We aim to inspire and empower all employees on their STEM2D journeys through access, engagement and skill development. Together, we believe STEM2D professionals are powerful catalysts for change in the world.
At J&J, we are dedicated to the values in Our Credo. We aim to inspire and empower all employees on their STEM2D journeys through access, engagement and skill development. Together, we believe STEM2D professionals are powerful catalysts for change in the world.
Supporting youth
Johnson & Johnson seeks to cultivate STEM2D interest at an early age to help youth grow and develop in these areas, preparing and positioning them to pursue higher education and careers in STEM2D. Through creative problem-solving and play, we aim to spark enchantment with STEM2D subjects in young people around the globe.
Supporting professionals
At Johnson & Johnson, we believe inclusive teams broaden viewpoints, allowing greater potential for new discoveries and innovations. To that end, we are championing the power of many perspectives through reimagined attraction and development of the world’s best STEM2D talent.
-
The WiSTEM2D program is continuing to blend our heart, science and ingenuity to profoundly impact health for humanity for the next generation of leaders. We do so by building partnerships to open new doors, creating inspiring moments to honor all in STEM2D, playing the part of role models and mentoring one another throughout the fundamental stages of our lives.
Kathy WengelExecutive Vice President & Chief Technical Operations & Risk Officer
More from Johnson & Johnson
Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD
Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.
The future of immunology
Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.
Using your own cells to fight cancer
Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson is moving this cutting-edge therapy forward.